Public Release:  Tribendimidine shows promise against intestinal worms

PLOS

Researchers have reported positive results from a safety and efficacy study pertaining to tribendimidine, a broad-based treatment for intestinal worm infections. The group's results demonstrate the success of the new drug from China versus that of the standard albendazole for the treatment of hookworm, large roundworm, whipworm, and, for the first time, threadworm and tapeworm. The study was jointly implemented by researchers from the Swiss Tropical Institute in Basel, the National Institute of Parasitic Diseases (IPD) in Shanghai, the Yunnan Institute of Parasitic Diseases in Simao, China, and the Jiangsu Institute of Parasitic Diseases in Wuxi, China. Details are published October 15th in the open-access journal PLoS Neglected Tropical Diseases.

Globally, more than one billion people are infected with intestinal worms. These chronic infections negatively impact on child and maternal health, nutritional status, physical performance, and cognitive development. The current control strategy relies on drugs to reduce morbidity, ideally complemented by the provision of safe water and sanitation to curb transmission. Only four drugs are currently recommended by the World Health Organization for treating soil-transmitted helminth infections, making the potential development of drug resistance a concern. Tribendimidine belongs to a different chemical class than current worm treatments. The drug had been developed at IPD and Shandong Xinhua Pharmaceutical in Zibo, China, and was approved by the China State Food and Drug Administration in 2004.

The community-based study involved 123 individuals who were screened for intestinal helminth infections, and randomly allocated to tribendimidine or the widely used albendazole treatment (both at 200 mg for children aged 5-14 years and 400 mg for individuals aged 15 years and above). The researchers' administration of a single oral dose of tribendimidine cured up to 92% of the common soil-transmitted helminth infections in humans in a highly endemic setting in China. Encouraging results were also found against threadworm and tapeworm infections. After treatment, these two parasites were absent in 55% and 67% of those initially infected, respectively. The infection intensity of large roundworms and hookworms was significantly reduced by both drugs, and no adverse treatment-related events were noted among the final study cohort.

The obtained results need to be validated in larger patient cohorts and different epidemiological settings, and repeated dosing should be tested to further improve treatment outcomes.

###

PLEASE ADD THIS LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.plos.org/10.1371/journal.pntd.0000322 (links will go live on Wednesday, October 15)

CITATION: Steinmann P, Zhou X-N, Du Z-W, Jiang J-Y, Xiao S-H, et al. (2008) Tribendimidine and Albendazole for Treating Soil-Transmitted Helminths, Strongyloides stercoralis and Taenia spp.: Open-Label Randomized Trial. PLoS Negl Trop Dis 2(10): e322. doi:10.1371/journal.pntd.0000322

CONTACT:

Prof. Dr. Jürg UTZINGER
Department of Public Health and Epidemiology
Swiss Tropical Institute
Socinstrasse 57
CH-4051 Basel
+41 61 284 81 29
juerg.utzinger@unibas.ch

Dr. Peter STEINMANN
National Institute of Parasitic Diseases
Chinese Center for Disease Control and Prevention
207 Rui Jin Er Road
Shanghai 200025
People's Republic of China
+86 136 71 61 60 56
peter.steinmann@unibas.ch

Prof. Dr. ZHOU Xiao-Nong
National Institute of Parasitic Diseases
Chinese Center for Disease Control and Prevention
207 Rui Jin Er Road
Shanghai 200025
People's Republic of China
+86 21 64 73 80 58
ipdzhouxn@sh163.net

Disclaimer

This press release refers to an upcoming article in PLoS Neglected Tropical Diseases. The release is provided by the article authors and/or their institutions. Any opinions expressed in these releases or articles are the personal views of the journal staff and/or article contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the releases and articles and your use of such information.

About PLoS Neglected Tropical Diseases

PLoS Neglected Tropical Diseases (http://www.plosntds.org/) is a peer-reviewed, open-access journal devoted to the pathology, epidemiology, prevention, treatment, and control of the neglected tropical diseases, as well as public policy relevant to this group of diseases. All works published in PLoS Neglected Tropical Diseases are open access, which means that everything is immediately and freely available subject only to the condition that the original authorship and source are properly attributed. The Public Library of Science uses the Creative Commons Attribution License, and copyright is retained by the authors.

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.